Relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine

This bill establishes a West Virginia grant program to fund U.S. Food and Drug Administration (FDA) drug development trials for ibogaine, a substance being studied for treating opioid use disorder and related conditions. Eligible applicants (for-profit, nonprofit, or public entities) must submit detailed trial plans covering cardiac safety protocols, participant recruitment, and post-approval strategies for insurance coverage and uninsured access. The program requires applicants to seek FDA breakthrough therapy designation and establish trial sites equipped with cardiac intensive care. Funding is contingent on applicants matching state funds and committing to local biomedical industry development in West Virginia.